Effects of SQ 26,533 on @entity943 , ST-segment elevation and on @entity1188 size in anesthetized XXXX .

@entity4485 @entity1508 @entity235 @entity1188 @entity1540 @entity850 @entity943
The antiarrhythmic, antifibrillatory activities and the ability of SQ 26,533 to reduce @entity1188 size were investigated in the @entity235 models of @entity943 . In model 1, @entity1508 -anesthetized @entity235 were subjected to acute occlusion of left circumflex coronary artery (LCX) for 30 min followed by reperfusion. SQ 26,533 infused at 50 micrograms/kg/min for 45 min significantly reduced (78%) the incidence of @entity1540 during the 30-min ligation of LCX. In addition, four of seven @entity235 (57%) survived after reperfusion, in contrast to 100% mortality observed in untreated animals. In model 2, left anterior descending artery under @entity4485 anesthesia was occluded for 20 min and released. SQ 26,533 (2.5 mg/kg i.v.) given 1 hr before occlusion significantly reduced (81%) @entity1540 during acute occlusion and four of five animals (80%) survived left anterior descending artery reperfusion, unlike saline controls (100% mortality). Similar efficacy was seen in a feline model of @entity943 . The model 3 animals under @entity4485 anesthesia were occluded for 60 min followed by reperfusion of the LCX in the presence of critical @entity850 . SQ 26,533 (2.5 mg/kg every 90 min) given 50 min after LCX occlusion not only resulted in a significant reduction (91%) of postreperfusion @entity1540 for the entire 5-hr observation period but also significantly reduced (42%) the @entity1188 size at 24 hr. Antiarrhythmic doses of SQ 26,533 caused minimal hemodynamic changes, except for a marked decrease in heart rate.(ABSTRACT TRUNCATED AT 250 WORDS)
